Eben Tessari Sells 45,042 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 45,042 shares of the company's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the completion of the sale, the chief operating officer now owns 72,363 shares of the company's stock, valued at approximately $2,207,795.13. This trade represents a 38.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.38, for a total transaction of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $30.46, for a total transaction of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $26.41, for a total transaction of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.48, for a total transaction of $245,760.00.

Kiniksa Pharmaceuticals Stock Up 2.1%

Shares of KNSA traded up $0.57 during mid-day trading on Friday, hitting $28.30. 907,293 shares of the company's stock were exchanged, compared to its average volume of 516,217. The firm has a fifty day moving average of $25.12 and a two-hundred day moving average of $22.17. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of -202.13 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.69.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. During the same period in the prior year, the firm earned ($0.25) EPS. Kiniksa Pharmaceuticals's quarterly revenue was up 72.5% compared to the same quarter last year. On average, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on KNSA. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $38.80.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in shares of Kiniksa Pharmaceuticals by 6.4% during the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock worth $1,393,000 after acquiring an additional 3,745 shares during the period. Strs Ohio acquired a new stake in shares of Kiniksa Pharmaceuticals during the 1st quarter worth about $595,000. Acadian Asset Management LLC increased its position in shares of Kiniksa Pharmaceuticals by 170.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock worth $22,961,000 after purchasing an additional 651,700 shares in the last quarter. Fred Alger Management LLC acquired a new stake in Kiniksa Pharmaceuticals in the 1st quarter valued at about $485,000. Finally, Millennium Management LLC increased its position in Kiniksa Pharmaceuticals by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.